Drugs Made in America Acquisition CORP S-1 registration statements
Registration statements, filed ahead of a public offering, with the business description and financials a first-time investor sees.
NASDAQ
S-1/A: Drugs Made In America Acquisition Corp. Files Amendment No. 6 to Form S-1 Registration Statement
Drugs Made In America Acquisition Corp. files an amendment to its S-1 registration statement, primarily consisting of exhibits and updated signatures.
NASDAQ
S-1/A: Drugs Made In America Acquisition Corp. Files Amendment No. 5 to Form S-1 Registration Statement
Drugs Made In America Acquisition Corp., a blank check company, filed an amendment to its S-1 registration statement for a proposed $200 million initial public offering.
NASDAQ
Drugs Made In America Acquisition Corp., a blank check company focused on the pharmaceutical industry, has filed Amendment No. 4 to its registration statement for a proposed $200 million initial public offering.
NASDAQ
S-1/A: Drugs Made In America Acquisition Corp. Files Amendment No. 3 to Form S-1 for $200 Million IPO
Drugs Made In America Acquisition Corp., a blank check company targeting the pharmaceutical industry, has filed Amendment No. 3 to its Form S-1 registration statement for a $200 million initial public offering.
NASDAQ
Drugs Made In America Acquisition Corp. has filed an amendment to its registration statement for a $500 million initial public offering targeting the pharmaceutical industry.
NASDAQ
S-1/A: Drugs Made In America Acquisition Corp. Files Amendment No. 1 to Form S-1 for $500 Million IPO
Drugs Made In America Acquisition Corp., a blank check company targeting the pharmaceutical industry, has filed an amendment to its S-1 registration statement for a proposed $500 million initial public offering.
NASDAQ
S-1: Drugs Made In America Acquisition Corp. Files for $500 Million IPO Targeting Pharmaceutical Sector
Drugs Made In America Acquisition Corp., a newly formed blank check company, aims to raise $500 million through an IPO to pursue a business combination within the pharmaceutical industry.